Cognition Therapeutics, Inc. Operating Cash Flow
Cognition Therapeutics, Inc. (CGTX) reported Operating Cash Flow of -$8.60 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-07
- Cognition Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$3.05M.
- Cognition Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$5.54M.
- Cognition Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$3.44M.
- Cognition Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$5.65M.
- Cognition Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$24.59M.
- Cognition Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$28.47M.
- Cognition Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$16.02M.
- Cognition Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$18.53M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$3.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | -$8.60M 10-Q · filed 2026-08-07 | -$12.03M derived: sum of 3 quarters · filed 2026-08-07 | -$17.68M derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | -$5.54M 10-Q · filed 2026-05-08 | -$8.98M derived: sum of 2 quarters · filed 2026-05-08 | -$14.63M derived: sum of 3 quarters · filed 2026-05-08 | -$20.25M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | -$3.44M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | -$9.09M derived: sum of 2 quarters · filed 2026-03-26 | -$14.71M derived: sum of 3 quarters · filed 2026-08-07 | -$24.59M 10-K · filed 2026-03-26 |
| 2025-09-30 | -$5.65M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$11.27M derived: sum of 2 quarters · filed 2026-08-07 | -$21.15M 10-Q · filed 2025-11-06 | -$29.53M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | -$5.62M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | -$15.50M 10-Q · filed 2026-08-07 | -$23.88M derived: sum of 3 quarters · filed 2026-08-07 | -$30.73M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | -$9.88M 10-Q · filed 2026-05-08 | -$18.26M derived: sum of 2 quarters · filed 2026-05-08 | -$25.11M derived: sum of 3 quarters · filed 2026-05-08 | -$31.11M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | -$8.38M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | -$15.23M derived: sum of 2 quarters · filed 2026-03-26 | -$21.23M derived: sum of 3 quarters · filed 2026-03-26 | -$28.47M 10-K · filed 2026-03-26 |
| 2024-09-30 | -$6.85M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$12.85M derived: sum of 2 quarters · filed 2025-11-06 | -$20.09M 10-Q · filed 2025-11-06 | -$25.55M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | -$6.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$13.24M 10-Q · filed 2025-08-07 | -$18.70M derived: sum of 3 quarters · filed 2025-08-07 | -$22.86M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | -$7.24M 10-Q · filed 2025-05-07 | -$12.70M derived: sum of 2 quarters · filed 2025-05-07 | -$16.86M derived: sum of 3 quarters · filed 2025-05-07 | -$20.56M derived: sum of 4 quarters · filed 2025-05-07 |
| 2023-12-31 | -$5.46M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | -$9.62M derived: sum of 2 quarters · filed 2025-03-20 | -$13.31M derived: sum of 3 quarters · filed 2025-03-20 | -$16.02M 10-K · filed 2025-03-20 |
| 2023-09-30 | -$4.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$7.86M derived: sum of 2 quarters · filed 2024-11-13 | -$10.56M 10-Q · filed 2024-11-13 | -$20.75M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | -$3.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$6.40M 10-Q · filed 2024-08-08 | -$16.59M derived: sum of 3 quarters · filed 2024-08-08 | -$16.59M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$2.71M 10-Q · filed 2024-05-07 | -$12.89M derived: sum of 2 quarters · filed 2024-05-07 | -$12.89M derived: sum of 3 quarters · filed 2024-05-07 | -$18.25M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | -$10.18M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | -$10.19M derived: sum of 2 quarters · filed 2024-03-26 | -$15.54M derived: sum of 3 quarters · filed 2024-03-26 | -$18.53M 10-K · filed 2024-03-26 |
| 2022-09-30 | -$4.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | -$5.36M derived: sum of 2 quarters · filed 2023-11-02 | -$8.35M 10-Q · filed 2023-11-02 | -$8.25M derived: sum of 4 quarters · filed 2023-11-02 |
| 2022-06-30 | -$5.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$8.35M 10-Q · filed 2023-08-08 | -$8.24M derived: sum of 3 quarters · filed 2023-08-08 | -$10.29M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | -$2.99M 10-Q · filed 2023-05-04 | -$2.89M derived: sum of 2 quarters · filed 2023-05-04 | -$4.94M derived: sum of 3 quarters · filed 2023-05-04 | -$5.85M derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | $101.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | -$1.95M derived: sum of 2 quarters · filed 2023-03-23 | -$2.86M derived: sum of 3 quarters · filed 2023-03-23 | -$3.63M 10-K · filed 2023-03-23 |
| 2021-09-30 | -$2.05M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -$2.96M derived: sum of 2 quarters · filed 2022-11-14 | -$3.73M 10-Q · filed 2022-11-14 | -$4.21M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | -$910.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | -$1.68M 10-Q · filed 2022-08-09 | -$2.16M derived: sum of 3 quarters · filed 2022-08-09 | |
| 2021-03-31 | -$772.00K 10-Q · filed 2022-05-11 | -$1.25M derived: sum of 2 quarters · filed 2022-05-11 | ||
| 2020-12-31 | -$480.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | -$3.43M 10-K · filed 2022-03-30 | ||
| 2020-09-30 | -$2.95M 10-Q · filed 2021-11-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |